Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor
Calidi Biotherapeutics (NYSE: CLDI) has appointed Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor. This announcement comes as the company advances its targeted antitumor virotherapies through clinical development.
Dr. Clifton brings over 17 years of experience in drug development, early phase trials, and cancer immunotherapy. He previously served as CMO at Parthenon Therapeutics/Incendia Therapeutics and has been a practicing surgical oncologist in the US Army since 2013. His expertise includes advising over 20 companies and authoring more than 80 peer-reviewed publications.
The appointment aligns with Calidi's recent IND filing for a dose escalation trial of CLD-201 in adult patients with solid tumors. The company is developing two platforms: a systemic approach using extracellular enveloped viruses to target metastatic tumors, and an intratumoral approach using stem cells to protect and enhance virotherapy potency.
Calidi Biotherapeutics (NYSE: CLDI) ha nominato il Dr. Guy Travis Clifton come Chief Medical Officer, Consulente e Consigliere. Questo annuncio arriva mentre l'azienda avanza con le sue viroterapie antitumorali mirate attraverso lo sviluppo clinico.
Il Dr. Clifton porta con sé oltre 17 anni di esperienza nello sviluppo di farmaci, negli studi clinici nelle fasi iniziali e nell'immunoterapia oncologica. In precedenza ha ricoperto il ruolo di CMO presso Parthenon Therapeutics/Incendia Therapeutics ed è un oncologo chirurgico praticante nell'Esercito degli Stati Uniti dal 2013. La sua esperienza include la consulenza per oltre 20 aziende e la pubblicazione di più di 80 articoli sottoposti a revisione paritaria.
La nomina è in linea con la recente richiesta di IND di Calidi per uno studio di escalation della dose di CLD-201 in pazienti adulti con tumori solidi. L'azienda sta sviluppando due piattaforme: un approccio sistemico che utilizza virus avvolti extracellulari per mirare ai tumori metastatici e un approccio intratumorale che utilizza cellule staminali per proteggere e migliorare la potenza della viroterapia.
Calidi Biotherapeutics (NYSE: CLDI) ha nombrado al Dr. Guy Travis Clifton como Director Médico, Consultor y Asesor. Este anuncio llega mientras la empresa avanza en sus viroterapias antitumorales dirigidas a través del desarrollo clínico.
El Dr. Clifton aporta más de 17 años de experiencia en el desarrollo de medicamentos, ensayos en fases tempranas y en inmunoterapia contra el cáncer. Anteriormente, se desempeñó como CMO en Parthenon Therapeutics/Incendia Therapeutics y ha sido oncólogo quirúrgico en el Ejército de EE. UU. desde 2013. Su experiencia incluye asesorar a más de 20 empresas y autorar más de 80 publicaciones revisadas por pares.
La designación se alinea con la reciente presentación de IND de Calidi para un ensayo de escalamiento de dosis de CLD-201 en pacientes adultos con tumores sólidos. La empresa está desarrollando dos plataformas: un enfoque sistémico que utiliza virus envueltos extracelulares para dirigirse a tumores metastásicos, y un enfoque intratumoral que utiliza células madre para proteger y mejorar la potencia de la viroterapia.
Calidi Biotherapeutics (NYSE: CLDI)는 Dr. Guy Travis Clifton을 최고 의료 책임자, 컨설턴트 및 고문으로 임명했습니다. 이 발표는 회사가 임상 개발을 통해 표적 항종양 바이로테라피를 발전시키고 있는 가운데 이루어졌습니다.
Clifton 박사는 약물 개발, 초기 단계 시험 및 암 면역 요법에서 17년 이상의 경험을 가지고 있습니다. 그는 이전에 Parthenon Therapeutics/Incendia Therapeutics에서 CMO로 근무했으며, 2013년부터 미 육군에서 외과 종양 전문의로 활동해왔습니다. 그의 전문 분야에는 20개 이상의 회사에 대한 자문과 80편 이상의 동료 검토 논문 저작이 포함됩니다.
이번 임명은 성인 고형 종양 환자를 대상으로 한 CLD-201의 용량 증량 시험을 위한 Calidi의 최근 IND 제출과 일치합니다. 회사는 전이성 종양을 표적으로 하는 세포외 피복 바이러스를 사용하는 전신 접근법과 바이로테라피의 효능을 보호하고 강화하기 위해 줄기 세포를 사용하는 종양 내 접근법의 두 가지 플랫폼을 개발하고 있습니다.
Calidi Biotherapeutics (NYSE: CLDI) a nommé le Dr. Guy Travis Clifton au poste de Directeur Médical, Consultant et Conseiller. Cette annonce intervient alors que l'entreprise fait avancer ses virothérapies antitumorales ciblées à travers le développement clinique.
Le Dr. Clifton apporte plus de 17 ans d'expérience dans le développement de médicaments, les essais précoces et l'immunothérapie contre le cancer. Il a précédemment occupé le poste de CMO chez Parthenon Therapeutics/Incendia Therapeutics et est oncologue chirurgical praticien dans l'armée américaine depuis 2013. Son expertise inclut le conseil à plus de 20 entreprises et la rédaction de plus de 80 publications évaluées par des pairs.
La nomination s'aligne avec le récent dépôt d'IND de Calidi pour un essai d'escalade de dose de CLD-201 chez des patients adultes atteints de tumeurs solides. L'entreprise développe deux plateformes : une approche systémique utilisant des virus enveloppés extracellulaires pour cibler les tumeurs métastatiques, et une approche intratumorale utilisant des cellules souches pour protéger et améliorer la puissance de la virothérapie.
Calidi Biotherapeutics (NYSE: CLDI) hat Dr. Guy Travis Clifton zum Chief Medical Officer, Berater und Gutachter ernannt. Diese Ankündigung erfolgt, während das Unternehmen seine gezielten antitumoralen Virotherapien durch klinische Entwicklungen vorantreibt.
Dr. Clifton bringt über 17 Jahre Erfahrung in der Arzneimittelentwicklung, frühen klinischen Studien und der Krebsimmuntherapie mit. Zuvor war er CMO bei Parthenon Therapeutics/Incendia Therapeutics und praktizierender chirurgischer Onkologe in der US-Armee seit 2013. Seine Expertise umfasst die Beratung von über 20 Unternehmen und die Autorenschaft von mehr als 80 peer-reviewed Publikationen.
Die Ernennung steht im Einklang mit Calidis kürzlicher IND-Einreichung für eine Dosissteigerungsstudie von CLD-201 bei erwachsenen Patienten mit soliden Tumoren. Das Unternehmen entwickelt zwei Plattformen: einen systemischen Ansatz, der extrazelluläre umhüllte Viren zur Zielung metastatischer Tumoren nutzt, und einen intratumoralen Ansatz, der Stammzellen verwendet, um die Virotherapie zu schützen und deren Potenz zu steigern.
- Recent IND filing for CLD-201 trial indicates progress in clinical development pipeline
- Appointment of experienced CMO with 17 years of relevant expertise strengthens leadership team
- Development of two distinct therapeutic platforms targeting both metastatic and solid tumors
- Both therapeutic platforms still in early clinical development stages
- No reported efficacy or safety data from current trials
SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor.
“With our recently filed IND for a company sponsored, dose escalation trial of CLD-201 in adult patients with solid tumors, Dr. Clifton’s oncology and advisory experience will be invaluable to us and our goal to advance our stem cell-based and enveloped virus platforms through the clinic and to patients in need,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. “I am delighted to welcome Dr. Clifton to our leadership team, and I look forward to leveraging his deep oncological experience to support the continued growth of Calidi going forward.”
Dr. Clifton is a practicing surgical oncologist with over 17 years of experience in drug development, early phase and translational clinical trials, and cancer immunotherapy. From 2013 to current, he has served as a practicing surgical oncologist in the US Army. He also served as the Chief Medical Officer and co-founder of Parthenon Therapeutics / Incendia Therapeutics from October 2020 to August 2024. He has worked with over 20 companies in an advisory role and has over 80 peer-reviewed publications on cancer and related topics. As a Colonel in the Army, he served on multiple deployments including four to Afghanistan, as well as to New York City in response to the COVID-19 pandemic. Dr. Clifton received his Bachelor of Science in Chemistry from the United States Military Academy, West Point, and Doctor of Medicine from Vanderbilt University; completed his residency in General Surgery from the Brooke Army Medical Center; and fellowship in General Surgical Oncology at the University of Texas MD Anderson Cancer Center.
“I am excited to join Calidi at such a pivotal time for the company, developing two cutting-edge immunotherapies. Calidi’s systemic approach, a platform using extracellular enveloped viruses, is designed to target and kill metastatic tumor cells while delivering a powerful payload. Its intratumoral approach, a platform that is designed to target and kill solid tumors, uses stem cells to protect and amplify the potency of the virotherapy. In both cases, the unique approach protects the virotherapy from the body's immune system during administration. These novel approaches have the potential to transform the way we treat cancer,” said Dr. Clifton, newly-appointed Chief Medical Officer, Consultant and Advisor of Calidi.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies, are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company’s periodic reports filed with the SEC on (i) Form 10-K filed on March 31, 2025. These reports may be amended or supplemented by other reports we file with the SEC from time to time.
Corporate Communications:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
CLDI@redchip.com
Source: Calidi Biotherapeutics, Inc.
FAQ
What is the significance of Dr. Clifton's appointment as CMO for CLDI's clinical trials?
What are the two main therapeutic platforms being developed by CLDI?
What is Dr. Clifton's background and experience prior to joining CLDI?
What is the current development status of CLDI's CLD-201 therapy?
